Skin Analytics Snapshot
Healthcare Services & HospitalsIndustry
We aim to help more people survive skin cancer by using AI to enable innovative skin cancer pathways that deliver better patient outcomes that are sustainable for health systems globally.
We’re working for a world where no one dies from skin cancer by deploying our AI medical device, DERM, to create the world’s most advanced skin cancer pathways.
Skin Analytics are proud to work with NHS dermatology teams to deploy AI-powered skin cancer pathways.
Our pathways enable NHS organisations to discharge benign lesions earlier in the pathway and therefore tackle backlog, free up out-patient delays and crucially, reserve limited dermatology capacity to prioritise patients with skin cancer by focusing on providing potentially life-saving treatment.
Some things we’re a little bit proud of:
🚀We’ve deployed with 13 NHS partners across primary and secondary care since 2020
➕ 8 more NHS partners are due to launch by summer 2024
🥇We’re the first and only AI skin cancer pathway within the NHS
✅DERM is the only UKCA approved Class IIa AI as a Medical Device for dermatology
🤯DERM is used in pathways that have seen over 81,000 NHS patients and identified more than 8,500 cancers
💪We’ve helped NHS organisations avoid 64% of face-to-face appointments in secondary care
🤳We provide Bupa and Vitality's remote skin assessment service
❤️Everything we do is in pursuit of better patient outcomes that are sustainable for health systems, globally
Skin Analytics are proud to work with NHS dermatology teams to deploy AI-powered skin cancer pathways.
Our pathways enable NHS organisations to discharge benign lesions earlier in the pathway and therefore tackle backlog, free up out-patient delays and crucially, reserve limited dermatology capacity to prioritise patients with skin cancer by focusing on providing potentially life-saving treatment.
Some things we’re a little bit proud of:
🚀We’ve deployed with 13 NHS partners across primary and secondary care since 2020
➕ 8 more NHS partners are due to launch by summer 2024
🥇We’re the first and only AI skin cancer pathway within the NHS
✅DERM is the only UKCA approved Class IIa AI as a Medical Device for dermatology
🤯DERM is used in pathways that have seen over 81,000 NHS patients and identified more than 8,500 cancers
💪We’ve helped NHS organisations avoid 64% of face-to-face appointments in secondary care
🤳We provide Bupa and Vitality's remote skin assessment service
❤️Everything we do is in pursuit of better patient outcomes that are sustainable for health systems, globally
